Sangamo Therapeutics, Inc. (SGMO)

Market Cap	108.56M
Revenue (ttm)	81.71M
Net Income (ttm)	-64.59M
Shares Out	237.60M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,415,168
Open	0.4500
Previous Close	0.4826
Day's Range	0.4200 - 0.4643
52-Week Range	0.4111 - 3.1790
Beta	1.19
Analysts	Buy
Price Target	4.50 (+884.9%)
Earnings Date	Aug 7, 2025

About THRX

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 183
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO
• Website: https://www.sangamo.com

Financial Performance

In 2024, Sangamo Therapeutics's revenue was $57.80 million, a decrease of -67.20% compared to the previous year's $176.23 million. Losses were -$97.94 million, -62.01% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price target is $4.5, which is an increase of 884.90% from the latest price.

Price Target

$4.5

(884.90% upside)

Analyst Consensus: Buy